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Abstract Small-cell lung cancer (SCLC) is an aggressive
neuroendocrine carcinoma that accounts for approximately
10–15 % of all lung cancer cases. This histological subtype
is a distinct entity with biological and oncological features
differing from non-small cell lung cancer (NSCLC).
Treatment is mainly performed using systemic chemother-
apy, although surgery in association with chemotherapy
may be indicated for a minor proportion of limited-disease
cases. Since the outcomes after surgical intervention in
patients with very early disease are comparable to those for
NSCLC, accurate clinical staging is required, particularly in
terms of nodal involvement. In addition to conventional
mediastinoscopy, positron emission tomography-computed
tomography and endobronchial ultrasonography guided
transbronchial needle aspiration have recently become
available for node diagnosis. The significance of surgery for
SCLC includes local disease control and treatment for cases
showing mixed histology. However, only two randomized
control studies have examined the efficacy of surgery in
SCLC, and both yielded negative results and are out of date.
We review herein several studies concerning surgery for
SCLC and discuss the results from a practical standpoint.
A prospective trial performed in collaboration with
pulmonologists is required to address the significance of
surgery, which is a limited option in the treatment of SCLC.
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Introduction
The American Cancer Society estimated that 221,130 new
cases of lung cancer of all histological types and 156,940
deaths from lung cancer occurred in the United States in
2011 [1]. Small-cell lung cancer (SCLC) accounts for
10–15 % of all lung cancers and is recognized as a high-
grade malignancy with rapid growth of the primary lesion
and a propensity for spread to mediastinal lymph nodes or
distant organs. Since SCLC is derived from neuroendocrine
cells and is biologically different from non-small cell lung
cancer (NSCLC), the staging system and treatment strategy
have been considered as for a distinct disorder among lung
cancers. Treatment for limited disease (LD)-SCLC typi-
cally comprises 4–6 courses of systemic chemotherapy
with concurrent thoracic irradiation. Prophylactic cranial
irradiation is also recommended in complete responders.
The standard regimen for LD-SCLC is cisplatin/etoposide,
as mentioned in the National Comprehensive Cancer
Network (NCCN) guideline in 2012 [2].
The Japan Lung Cancer Registry Study (JLCRS) enrol-
led surgical and non-surgical cases in 2002, and showed a
5-year survival rate of 14.7 % for SCLC, worse than the
46.8 % for NSCLC [3]. This outcome may reflect the higher
proportion of advanced disease rather than any high-grade
behavior of SCLC. Indeed, the proportions of patients at
c-stage III/IV have been reported as 83.9 and 43.1 % for
SCLC and NSCLC, respectively, in the literature [4].
However, radical operation is still practically performed in
patients with early LD without node involvement, although
some of these cases are postoperatively diagnosed with
SCLC. Interestingly, JLCRS found that surgically resected
cases in 2004 showed a 5-year survival rate for all resected
cases of 52.6 % for SCLC, comparable to those for squa-
mous (59.1 %), large (53.3 %), and adenosquamous cell
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carcinomas (50.8 %) [4]. Few clinical studies to date have
examined the efficacy of surgical resection for SCLC. This
review is focused on the current consensus regarding sur-
gical intervention for SCLC.
Diagnosis
SCLC is usually diagnosed based on immunohistochemical
examination for neuroendocrine markers such as chro-
mogranin, synaptophysin, or CD56, in addition to mor-
phological hematoxylin-eosin staining using transbronchial
biopsy specimens. Since we have a greater chance of
encountering small-sized lung cancers, thanks to the
widespread use of Computed Tomography (CT) screening
and improvements in CT resolution, the possibility of
SCLC should be always considered even among clinically
early lung cancers. Significant elevations in levels of tumor
markers such as pro-gastrin-releasing peptide (ProGRP) or
neuron-specific enolase (NSE) are also valuable indicators.
The sensitivity of ProGRP is reportedly 95 %, making this
marker useful in the diagnosis of SCLC [5].
Staging
Staging system
SCLC has been practically classified using a two-stage
system initially proposed by the Veterans Administration
Lung Study Group (VALG) in 2002, as either LD confined
to the hemithorax or extensive disease (ED) extending
beyond the ipsilateral hemithorax [6]. The tumor, node,
metastasis (TNM) system, which is generally used for
NSCLC staging and is beneficial in resectable cases, has
been recognized as largely ineffective for SCLC, because
resectable cases represent a very minor population.
Version 7 of the TNM staging system was recently pro-
posed by the International Association for the Study of Lung
Cancer (IASLC) and 12,620 SCLC cases were analyzed [7].
Among those, 349 patients (2.8%) underwent surgical resec-
tion and the 5-year survival rates were 56, 57, 38, 40, 12, and
0 % for p-stage IA, IB, IIA, IIB, IIIA, and IIIB, respectively
[8]. TNM classification could thus be of use for resectable
SCLC, albeit with worse survival rates than for NSCLC.
When considering surgical indications in SCLC, TNM stag-
ing could be more useful than LD/ED staging, while the
problem regarding similar outcomes between p-stage IA and
IB, and IIA and IIB should be resolved in the future.
Lymph node evaluation
Pre-treatment evaluation, especially for lymph node
metastasis, is quite important to decide operative indications
for early SCLC. Positron emission tomography (PET) is a
powerful diagnostic imaging that is reportedly useful in
SCLC staging [9, 10]. Although the level of evidence is
currently insufficient, PET could be useful in SCLC staging
[11]. The initial staging of SCLC using PET-CT has shown
93 % sensitivity and 100 % specificity, more accurate than
conventional staging with CT, bone scintigraphy, or bone
marrow biopsy [12]. This suggests that PET-CT could
become one of the key modalities for diagnostic imaging in
the selection of resectable SCLC patients.
Pathological mediastinal node diagnosis is convention-
ally performed using mediastinoscopy. For approachable
mediastinal lymph nodes, the sensitivity, specificity, and
accuracy are 66.7, 100, and 94.6 %, respectively [13]. This
study also emphasized that mediastinal metastasis (p-N2
disease) was found in 4 of 8 (50%) c-N1 cases. JCOG9101
also showed similar results for lymph node metastatic
findings, with 5 of 9 (56%) c-N1 cases resulting in p-N2
postoperatively [14]. Video-assisted mediastinoscopy has
recently become available and the safety of the procedure
has improved. Mediastinoscopy is still a valuable proce-
dure to rule out locally advanced LD-SCLC. Another novel
technique for cytopathological node evaluation is endo-
bronchial ultrasound-guided transbronchial needle aspira-
tion (EBUS-TBNA). A retrospective study to investigate
the utility of EBUS-TBNA in patients with SCLC dem-
onstrated highly accurate lymph node staging with 96.4 %
sensitivity, 100 % specificity, and 97.2 % accuracy [15].
The 5-year survival rate among patients selected for sur-
gical treatment using EBUS-TBNA is reportedly 77.8 %.
Surgical intervention
Randomized-controlled studies
The efficacy of surgical intervention for SCLC remains
controversial. Only two randomized-controlled studies
have focused on addressing the significance of surgery in
SCLC patients [16, 17]. The first, a landmark study by the
British Medical Research Council, compared surgical
resection with radiation therapy and showed no superiority
of surgery [16]. After that publication, surgery for SCLC
decreased and chemotherapy has played a major role in
management. However, the conclusions of that investiga-
tion can no longer be considered applicable to current
practice, for several reasons. Patients enrolled in the study
had proximal lesions diagnosed using rigid bronchoscopy
and incomplete resection was performed in half of the
cases. The staging could be considered inaccurate, because
the diagnostic imaging available in that era was very lim-
ited, with no CT, PET, or mediastinoscopy. The other
randomized-controlled study from the Lung Cancer Study
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Group aimed to determine the benefits of additional surgery
for residual disease following response to systemic che-
motherapy using cyclophosphamide, doxorubicin, and vin-
cristine [17]. A total of 146 patients with LD-SCLC were
randomized, 70 to receive surgery and 76 to a non-surgery
group. Thoracic and cranial radiation was added in both
groups. Complete resection was achieved in 54 of 70 (77 %)
surgery patients. Median survival time was 15.4 months for
the surgery group and 18.6 months for the non-surgery
group, with no significant difference observed in survival.
The study concluded that additional pulmonary resection
had no benefit in multimodal treatment for SCLC. Although
that study enrolled only LD-SCLC cases, patients without
lymph node metastasis (pN0) accounted for only 29 of 70
(41 %) surgery patients, whereas such patients are consid-
ered the main candidates for surgery at present. No docu-
mentation of outcomes for pN0 patients in the study cohort
was given. Furthermore, the response rate to chemotherapy
was 65 %, substantially worse than that using cisplatin/
etoposide, the current standard protocol for LD-SCLC (the
response rate for which is 92–97 % in association with
thoracic irradiation) [18]. Thus, the implications of these
two randomized-controlled studies should be carefully
considered in terms of current SCLC management.
Surgery might contribute to local control
Systemic chemotherapy using cisplatin/etoposide with
concurrent thoracic irradiation is a standard treatment for
LD-SCLC [19]. Although early concurrent thoracic irra-
diation improved survival in several studies, locoregional
relapse is still frequent (26–63 %) [18, 20, 21]. Thoracic
irradiation could contribute to prevent local failure, as
local relapse was found in 90 % of patients treated with
chemotherapy alone [22]. In addition, an investigation
regarding metastatic sites using autopsy samples showed
residual disease with viable cancer cells at primary tumor
in 92 % of non-resected patients, while viable lesion was
observed in only 31 % after radical resection [23]. The
Japan Clinical Oncology Lung Cancer Study Group
(JCOG) carried out a phase II trial of adjuvant chemo-
therapy using cisplatin/etoposide for completely resected
I–IIIA SCLC [14]. The local failure rate was only 10 % in
that study. Surgery might thus contribute to local control
along with chemo-radiotherapy, and could thus be expected
to improve survival.
Results of surgical intervention
The results of surgical intervention for SCLC have been
reported from several groups (Table 1). The University of
Toronto Lung Oncology Group showed the efficacy of
adjuvant surgery in addition to chemotherapy, with a
5-year survival rate of 51 % in p-stage I SCLC patients,
and similar outcomes to NSCLC for p-stage II–IIIA [24].
The IASLC reported 5-year survival rates of 53 and 44 %
for p-stage IA and IB, respectively [8]. Analyses of 205
patients who underwent radical lobectomy from the
National Cancer Institute Surveillance Epidemiology and
End Results database showed a 5-year survival rate of
50.3 % in c-stage I SCLC and better outcomes than non-
surgical c-stage IA from the IASLC report [25]. They
therefore recommended surgery in the treatment of local-
ized SCLC. The Bronchogenic Carcinoma Cooperative
Group of the Spanish Society of Pneumology and Thoracic
Surgery (GCCB-S) presented results from a multicenter
study with a 5-year survival rate of 36 % for p-stage I [26].
JCOG 9101 reported 3-year survival rates of 68, 56, and
Table 1 Results of surgical intervention for small-cell lung cancer
Group (year) N Overall survival Chemotherapy Radiation
BMRC [16] (1973) 71 1YS: LD 21 % None None
LCSG [17] (1994) 70 2YS: LD 20 % CPA/VCR/DXR TRT 50 Gy
95 course PCI 30 Gy
TSSGO [27] (2000) 91 5YS: c-IA 49 %, IB 47 % Various TRT/PCI
p-IA 56 %, IB 30 %
JCOG [14] (2005) 62 5YS: c-IA 66 %, IB 65 % CDDP/VP16 None
p-IA 73 %, IB 67 % 9 4 course
GCCB [26] (2006) 47 5YS: p-IA/IB 36 % Various PCI
IASLC [8] (2009) 349 5YS: p-IA 53 %, IB 44 % Various Unknown
SEER [25] (2010) 247 5YS: c-IA/B 50 % Various Various
BMRC British Medical Research Council, LCSG Lung Cancer Study Group, TSSGO Thoracic Surgery Study Group of Osaka University, JCOG
Japan Clinical Oncology Group, GCCB Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic
Surgery, IASLC International Association for the Study of Lung Cancer, SEER Surveillance Epidemiology and End Results, LD limited-disease,
YS year survival, CPA cyclophosphamide, VCR vincristine, DXR doxorubicin, CDDP cisplatin, VP-16 etoposide, TRT thoracic radiation therapy,
PCI prophylactic cranial irradiation
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13 % in patients with c-stage I, II, and IIIA, respectively
[14]. The Thoracic Surgery Study Group of Osaka
University also reported surgical results, with 5-year survival
rates of 49.4 and 46.7 % in c-stage IA and IB, respectively
[27]. These results are similar to those from other reports so
far. Based on these historical studies, we suppose that the
indication for initial surgery should be limited to LD-SCLC
cases without lymph node involvement at present.
Adjuvant chemotherapy and prophylactic cranial
irradiation (PCI)
The 5-year survival rate in patients who received C4
courses of perioperative chemotherapy was 80.8 %, sig-
nificantly better than that in patients treated with 1–3
courses [27]. Addition of C4 courses of perioperative
chemotherapy was an independent prognostic factor in
multivariate analysis. Interestingly, all 4 patients with
pT0N0 stage 0 who showed complete response after pre-
operative chemotherapy also survived more than 5 years. A
prospective analysis of chemotherapy using cyclophos-
phamide, doxorubicin, and vincristine following surgery
showed a 5-year survival rate of 50 % in p-stage I and
35 % in p-stage II [28]. According to NCCN guideline
2012, adjuvant chemotherapy alone is recommended for
p-N0 SCLC patients who undergo complete resection,
while concurrent chemotherapy and mediastinal radiation
therapy should be considered in patients with lymph node
metastasis [2]. Furthermore, PCI is currently recommended
after adjuvant chemotherapy in patients with good status
who undergo complete resection [2]. PCI might also con-
tribute to the control of brain metastases, which are fre-
quently found in patients with p-stage II–III SCLC after
resection [29].
Surgical treatment for mixed histology
Another clinically significant indication of surgery for
SCLC is the treatment of mixed SCLC and NSCLC.
Resected primary lesions after chemotherapy reportedly
contained residual NCSLC histology in 10–25 % of
patients, sometimes even in cases that had shown complete
response to preoperative chemotherapy [17, 30, 31]. As
residual lesions after current systemic chemotherapy using
cisplatin/etoposide could contain chemo-resistant SCLC or
NSCLC, surgical resection following chemotherapy is
justified in such cases. We occasionally encounter com-
bined large cell neuroendocrine carcinoma (LCNEC) as a
postoperative pathological diagnosis that has been preop-
eratively diagnosed as SCLC based on a biopsy specimen.
Although LCNEC is currently classified as a subtype of
large cell carcinoma, the oncological behavior is similar to
SCLC and efficacy of adjuvant chemotherapy has been
reported in patients who undergo complete resection [32].
Adjuvant chemotherapy should thus be considered in
patients finally diagnosed with LCNEC following surgical
treatment despite preoperative diagnosis of SCLC.
In summary, the significance of surgical intervention
lies in achieving local control of the primary site and
treatment for NSCLC-mixed histology in SCLC. Surgery is
also performed in cases with undefined preoperative path-
ological diagnosis. Surgery clearly has a role to play in
multimodal treatment of early LD-SCLC without lymph
node involvement (Table 2). Further multicenter prospec-
tive clinical trials with a large sample size are expected to
be started according to evidence-based guidelines, although
the accrual of such very early LD-SCLC with operative
indications is extremely hard.
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